Research programme: long-acting gamma interferon - Bolder BioTechnology

Drug Profile

Research programme: long-acting gamma interferon - Bolder BioTechnology

Alternative Names: BBT-046; Gamma Interferon Long Acting; TNF-γ long acting

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bolder BioTechnology
  • Class Antifungals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mycoses

Most Recent Events

  • 04 Dec 2017 Long-acting gamma interferon is still in preclinical development for mycoses in USA (Bolder Biotechnology pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in USA (Parenteral)
  • 31 Aug 2010 Preclinical development in Immunodeficiency disorders is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top